
Sep 8, 2026
Endeavor BioMedicines Presents New Quantitative Imaging Data from Analysis of Phase 2a Clinical Trial Evaluating Taladegib (ENV-101) in Patients with Idiopathic Pulmonary Fibrosis
Findings presented at the European Respiratory Society Congress 2026 corroborate previous findings and provide continued clinical evidence supporting taladegibSAN DIEGO--(BUSINESS WIRE)--Endeavor BioMedicines ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today presented a quantitative imaging post hoc analysis from its Phase 2a trial evaluating its investigatio




